Sirtex, SingHealth to explore nanoparticles in treating cancer

12/6/2012 | Genetic Engineering & Biotechnology News

Sirtex Medical and SingHealth have entered a deal to develop the use of carbon-cage nanoparticles in treating cancer. The technology is based on Technegas, which is used in nuclear medicine as an inhalable aerosol of carbon-cage nanoparticles for detecting blood clots in the lungs. The first research initiative under the partnership will explore the technology as a treatment for advanced ovarian cancer that has metastasized in the abdomen and pelvic region.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ
Chief Executive Officer
UCare Minnesota
Minneapolis, MN
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC